The trial is a partnership between the country’s National Institute of Health and a Chinese vaccine company.
Pakistan will carry out the first Phase 3 clinical trials of Covid-19 vaccine, the National Command and Operation Centre (NCOC) announced on Tuesday.
The trial is a partnership between the country’s National Institute of Health (NIH) and CanSinoBio, a Chinese vaccine company.
Federal Minister for Planning and Development, Asad Umar, said a total of 40,000 people from seven different countries will participate in Phase 3 clinical trials. In a tweet, Umar added that of the 40,000 participants, around 8,000 to 10,000 will be from Pakistan and the initial results will be out in four to six months, reported The Express Tribune.
Just launched the phase 3 trials for a Covid19 vaccine in Pakistan. Vaccine has been developed by a chinese company. A total of 40,000 people will participate in this trial in 7 countries, of which 8 to 10, 000 will be Pakistani. Initial results expected in 4 to 6 months
– Asad Umar (@Asad_Umar) September 22, 2020
According to Dawn, Pakistan is among the countries which agreed to carry out Phase 3 clinical trials, the NCOC statement said. NIH Executive Director, Major General Aamer Ikram, said it was an “honour” for the country that it was participating in the Phase 3 trial of a vaccine for the first time.
“The entire world is looking towards a vaccine right now. There are seven vaccines for which trials are being conducted – three of them developed in China. This CanSino vaccine is based on recombinant technology in which an adino-vector is made deficient. The virus vector and cell culture has been procured from Canada,” Major General Ikram was quoted as saying in Dawn.
Click here to read more news from @khaleejtimes